drugset
Drugs / Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells
last change Sep 2021 re-read 3 minutes ago

Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells

Cell therapy

Developed for
COVID-19
Investigated by
Alicante Institute for Health and Biomedical Research (ISABIAL) · Clinica Universidad de Navarra, Universidad de Navarra · Hospital General Universitario Gregorio Marañon · Hospital General Universitario de Alicante · Hospital Universitario Virgen de la Arrixaca · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
+1 more · University of Salamanca

Trials 1

today NCT04348461 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04348461 May → Sep 2020 COVID-19 Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz Suspended No outcome recorded Stop: Business

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04348461 ↗
Modality Cell therapy “The investigational medicinal product consists of expanded allogeneic mesenchymal stromal cells derived from adipose tissue and administered intravenously.” NCT04348461 ↗
Route Intravenous “administered intravenously” NCT04348461 ↗